Brief: Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
12/05/2026 14:25
May 12 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK: RIBO ANNOUNCES STRATEGIC COLLABORATION WITH INSILICO MEDICINE TO ACCELERATE SIRNA DRUG DEVELOPMENT DRIVEN BY AI SUZHOU RIBO LIFE SCIENCE CO LTD - AND INSILICO MEDICINE TO COLLABORATE ON SIRNA DRUG DEVELOPMENT AND AI-POWERED DISCOVERY Source text: ID:nPreKZT8ca Further company coverage: 6938.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Suzhou Ribo Life Science
See all newsBrief: Suzhou Ribo Life Science To Buy Remaining 49.71% Of Target Company
Suzhou Ribo climbs on EU clinical trials application of RBD3133 for obesity
Brief: Suzhou Ribo Life Science Expects Revenue Of RMB311 Million-RMB436 Million For Six Months
Brief: Suzhou Ribo Life Science Says EMA Approves Initiation Of Phase 2B Trial Of Vortosiran
CEO Purchases 6800 H Shares On Open Market